GET DAILY SIGNALSBSX vs JNJ: JNJ's +29% YTD Gain Stands Out Against BSX Pressure
Key Takeaways
- BSX has been pressured in recent weeks by a cybersecurity disruption, reduced full-year guidance, and share erosion in its electrophysiology (EP) and WATCHMAN franchises.
- JNJ recently raised its 2026 outlook, with pharmaceutical growth offsetting the loss of exclusivity (LOE) on Stelara, though its MedTech segment has decelerated.
- On a relative performance basis, BSX has fallen sharply over the past year while JNJ has gained roughly 29% year to date, a wide divergence in market positioning.
- Tickeron AI Verdict: Based on trend consistency, stability, and catalysts, Tickeron's AI would currently favor JNJ over BSX.
- For deeper coverage, explore BSX Major News and BSX Today's Price Move, as well as JNJ Major News and JNJ Today's Price Move.
- To see which automated strategies are currently leading the market, explore Trending AI Robots.
Introduction
This stock comparison examines two healthcare giants with very different recent trajectories: Boston Scientific Corporation (BSX), a medical-device leader focused on cardiovascular and interventional technologies, and Johnson & Johnson (JNJ), a diversified pharmaceutical and MedTech conglomerate. The two names sit at opposite ends of the sentiment spectrum, making the pairing useful for investors weighing high-growth device franchises against a stable, dividend-paying defensive holding. Traders monitoring momentum, sector rotation, and relative performance may find this comparison particularly relevant in the current market environment. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
BSX Overview and Recent Performance
Boston Scientific manufactures medical devices across interventional cardiology, electrophysiology, neuromodulation, and structural heart categories such as WATCHMAN. Recent market activity has been challenging. An August cybersecurity incident disrupted manufacturing, order processing, and global shipments, and the company estimated the event reduced recent quarterly sales growth by roughly 300 basis points (bps), where one basis point equals 0.01 percentage point. Management lowered its full-year 2026 guidance, now expecting organic sales growth of about 3.75% and adjusted earnings per share (EPS) of $3.16–$3.18, down from prior ranges.
Beyond the cyber impact, two previously important growth engines have weakened. Electrophysiology (the treatment of heart-rhythm disorders) sales declined amid intensifying competition in pulsed field ablation, and WATCHMAN sales fell as market dynamics softened. Management has signaled that 2027 may represent the trough of the current cycle, with a return to stronger growth targeted in 2028. The stock has traded near multi-year lows in recent weeks, reflecting lowered expectations despite strength in interventional cardiology and neuromodulation. From what I see, this reset looks extended.
JNJ Overview and Recent Performance
Johnson & Johnson operates two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). In its most recent quarter, total revenue rose roughly 5.9% to about $25.4 billion, and adjusted EPS of $2.59 exceeded consensus. The company raised its full-year 2026 sales outlook to approximately $101.2 billion. Pharmaceutical momentum has been the story, with drugs such as Tremfya, Darzalex, Carvykti, and Rybrevant growing strongly and offsetting the loss of exclusivity on Stelara, which faces biosimilar competition.
The MedTech division has been a softer spot, with growth decelerating to the low single digits amid Middle East disruption, European spending constraints, and pricing pressure in China. A large pre-tax charge tied to the proposed talc litigation settlement depressed reported earnings in the latest quarter. Despite these headwinds, the company maintains a substantial dividend and generally defensive financial profile, and the stock has delivered strong year-to-date gains compared with the broader healthcare sector. I’m watching this closely as the pharma offset continues to support the overall picture.
Head-to-Head Comparison
The two companies diverge sharply across several dimensions. In terms of business model, BSX is a focused medical-device pure play whose valuation depends heavily on product-cycle momentum in EP and structural heart, while JNJ offers diversified exposure across pharmaceuticals and devices, buffering any single product's weakness. On growth drivers, JNJ's oncology, immunology, and neuroscience franchises are currently carrying performance, whereas BSX is working through a down-cycle in two core franchises despite strength elsewhere in its portfolio.
Recent momentum clearly favors JNJ, which has gained year to date, while BSX has suffered a steep decline and traded near multi-year lows. Risk factors also differ: BSX faces execution and competitive risks tied to product launches and the lingering cyber disruption, while JNJ contends with MedTech deceleration, talc litigation, and the Stelara patent cliff. Sector exposure is similarly distinct—BSX is concentrated in cardiovascular devices, while JNJ spans drugs, immunology, oncology, and surgical technologies. These trade-offs mean the two stocks appeal to different investor profiles.
Tickeron AI Verdict
Based on observable factors including trend consistency, stability, relative positioning, and near-term catalysts, Tickeron's AI would likely favor JNJ over BSX in the current environment. JNJ's combination of raised guidance, pharmaceutical momentum, and positive year-to-date trend provides a steadier backdrop, while BSX is navigating a multi-quarter reset with declining near-term growth. Because this assessment relies on probabilistic signals rather than guarantees, conditions could shift as new data emerges. The verdict reflects relative positioning today rather than a permanent judgment on either company's long-term prospects. One thing that stands out is how the stability edge tilts the scale here.
Exploring Automated Strategies
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies drawn from hundreds of available AI Trading Bots that monitor thousands of different tickers. These bots employ diverse trading styles, strategies, timeframes, risk profiles, and performance statistics, and they trade varying sets of securities. Only the most suitable strategies for current market conditions earn a place in this curated section, helping traders identify which approaches are resonating with the present environment. For those seeking an objective, data-driven lens on names like BSX and JNJ, exploring Trending AI Robots can provide useful perspective on automated market positioning.
Using Tickeron’s AI Tools for Research
In my own analysis, I find Tickeron’s AI Daily Buy/Sell Signals helpful for spotting shifts in momentum across healthcare names like these. The platform lets me quickly compare trend consistency and stability without sifting through endless charts. It has become a regular part of how I cross-check relative positioning before forming a view on pairs like BSX and JNJ.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JNJ in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Oscillator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.360). P/E Ratio (31.640) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement